Withus Pharmaceutical Co Ltd

Withus Pharmaceutical Co Ltd maintains a conservative capital structure, with a debt-to-equity ratio of 0.21, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.81, suggesting it can cover its short-term obligations but with limited excess capacity. Free cash flow is negative at -150.18 million KRW, which may signal reinvestment in operations or capital expenditures, as evidenced by the -3.06 billion KRW in capital expenditure.

Profitability metrics show a return on equity (ROE) of 2.22% and a return on assets (ROA) of 1.53%, both below the typical thresholds for high-performing pharmaceutical firms. The company's gross profit margin is 67.2%, which is in line with industry norms, but its operating margin of 11.16% is relatively modest, indicating potential inefficiencies in cost control or pricing power.

Geographically, Withus Pharmaceutical Co Ltd is heavily concentrated in the South Korean market, with no disclosed international revenue streams. This concentration increases exposure to domestic regulatory and economic shifts. The company does not report segment-specific revenue, but its product portfolio likely includes both branded and generic pharmaceuticals, as is common in the industry.

Looking ahead, the company is projected to see a modest growth in revenue, with a current FY outlook of 2.5% and a next FY outlook of 3.0%. These figures are in line with the broader industry's conservative growth expectations, driven by stable domestic demand and limited international expansion.

Risk factors include a medium liquidity risk, as the company's net cash position is negative after subtracting total debt, and a low dilution risk, with no significant dilution potential in the near term. The company's risk assessment also highlights the importance of maintaining a stable cash flow to support ongoing operations and capital expenditures.

Recent events include the filing of its latest financial report, which disclosed the current financial snapshot and valuation metrics. No significant earnings call transcripts or regulatory filings have been reported in the recent period that would suggest a material change in the company's strategic direction or financial health.

Free cash flow surged 771.8% year-over-year to 5.9 billion KRW, showing dramatic improvement in cash generation.

Revenue grew at a 16.7% CAGR over four years, reflecting consistent top-line expansion despite recent volatility.

Debt-to-equity ratio of 0.21 is below the cohort median of 0.18, suggesting a conservative capital structure.

The company faces high credit risk, indicating potential difficulties in meeting financial obligations or securing financing.

Medium liquidity risk suggests potential challenges in meeting short-term financial obligations or operational needs.